<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521596</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_BIOWM</org_study_id>
    <nct_id>NCT03521596</nct_id>
  </id_info>
  <brief_title>Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS</brief_title>
  <acronym>FIL_BIOWM</acronym>
  <official_title>Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter retrospective and prospective observational study including patients with WM or
      IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly
      sensitive techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter retrospective and prospective observational study including patients with WM or
      IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly
      sensitive techniques such as flow cytometry, real time quantitative PCR (RT-qPCR), digital
      droplet PCR (dd-PCR) and NGS, in order to: evaluate the mutational status on genomic DNA or
      cell-free DNA and compare the results to assess the most reliable source for mutation
      studies; perform and compare molecular and flow cytometry analyses on bone marrow, peripheral
      blood (both analyses), plasma and urine samples (only molecular analysis) to assess the best
      source for diagnosis and MRD monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of mutation</measure>
    <time_frame>22 months</time_frame>
    <description>To demonstrate that the rate of mutations of MYD88 (L265P) and/or CXCR4 (S338X) detected in peripheral blood and/or urine show a negligible difference with the rate of mutations detected in bone marrow samples (BM, gold standard)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Patient enrolled</arm_group_label>
    <description>Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRD and clonal evolution</intervention_name>
    <description>Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques</description>
    <arm_group_label>Patient enrolled</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include either IgM-MGUS, asymptomatic WM or symptomatic WM
        patients requiring treatment. Patients in need of therapy will be treated according to
        recently published guidelines [49]. Patients treated with new agents, including the BTK
        inhibitor Ibrutinib, will be included. Patient enrolled retrospectively will constitute the
        learning cohort of the study, while those enrolled prospectively will constitute the
        validation cohort).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IgM monoclonal gammopathy of undetermined significance (Ig-MGUS) or
             Waldenström's Macroglobulinemia (WM) according to criteria established at the second
             International Workshop on Waldenström's Macroglobulinemia [1]

          -  Age ≥ 18 years

          -  Previously untreated patients (only for the prospective cohort)

          -  Symptomatic or asymptomatic disease

          -  Subject understands and voluntarily signs an informed consent form approved by an
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB)

        Exclusion Criteria:

          -  Active HBV, HCV or HIV infection (antiHBc+ patients with undetectable HBV-DNA are
             eligible to the study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marzia Varettoni</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pavia - IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marzia Varettoni</last_name>
    <phone>038250</phone>
    <phone_ext>3082</phone_ext>
    <email>m.varettoni@smatteo.pv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Ferrero</last_name>
    <phone>011633</phone>
    <phone_ext>6884</phone_ext>
    <email>sferrero2@cittadellasalute.to.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Tedeschi</last_name>
      <email>alessandra.tedeschi@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Tedeschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e Cesare Arrigo SC Ematologia</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Ladetto</last_name>
      <email>marco.ladetto@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>Marco Ladetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SOS Ematologia Ospedale C. Massaia</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mmarchetti@asl.at.it</email>
    </contact>
    <investigator>
      <last_name>Monia Marchetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe R Nunziata</last_name>
      <email>grnunziata@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Rodolfo Nunziata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II - UOC Ematologia</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giacomo Loseto</last_name>
      <email>loseto.giacomo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giacomo Loseto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Barletta</name>
      <address>
        <city>Barletta</city>
        <zip>76121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <phone>3464142695</phone>
      <email>giuseppe.tarantini0@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Università degli Studi della Campania Luigi Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>antonello.sica@fastwebnet.it</email>
    </contact>
    <investigator>
      <last_name>Antonello Sica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>dario.marino@iov.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Dario Marino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia AO di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Piazza</last_name>
      <email>francesco.piazza@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Piazza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti Villa Sofia-Cervello, Divisione di Ematologia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Patti</last_name>
      <email>k.patti@villasofia.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Patti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>fre@ao.pr.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marzia Varettoni, M.D.</last_name>
      <phone>00390382503595</phone>
      <email>m.varettoni@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Marzia Varettoni, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Arcispedale Santa Maria Nuova - IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ferrari.angela@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Angela Ferrari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47924</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona Tomassetti</last_name>
      <email>simona.tomassetti@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Simona Tomassetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>luca.laurenti@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Luca Laurenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia, AOU Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>encioema@libero.it</email>
    </contact>
    <investigator>
      <last_name>Emanuele Cencini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Città della Salute e della Scienza Ematologia Universitaria</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simone Ferrero, MD</last_name>
      <email>sferrero2@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Simone Ferrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Clinica Ospedale Maggiore</name>
      <address>
        <city>Trieste</city>
        <zip>34121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>g.pozzato@fmc.units.it</email>
    </contact>
    <investigator>
      <last_name>Gabriele Pozzato, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine (A.S.U.I. Udine) - PO S. Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>francesco.zaja@asuiud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Zaja, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Merli, MD</last_name>
      <email>michele.merli@ospedale.varese.it</email>
    </contact>
    <investigator>
      <last_name>Michele Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgM monoclonal gammopathy</keyword>
  <keyword>Waldenström's Macroglobulinemia</keyword>
  <keyword>Minimal residual disease</keyword>
  <keyword>Clonal evolution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

